Clobetasol Propionate Shampoo Recall Due to Manufacturing Compliance Issues
Akorn, Inc. is recalling all lots of Clobetasol Propionate Shampoo, 0.05% distributed nationwide after the firm closed and could not continue required stability studies.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall without reported illnesses, injuries, or deaths. The hazard is procedural—incomplete stability data due to manufacturer closure—rather than an active contamination or defect. When no illnesses or injuries are reported and the hazard is theoretical, the score is at most 3; the procedural nature places it in the Moderate category.
Plain-English summary
Akorn, Inc. is recalling all lots of Clobetasol Propionate Shampoo, 0.05%, a prescription-only topical medication. The product was distributed nationwide in the USA and Puerto Rico under all NDCs.
The recall was issued because the manufacturer ceased operations and could not complete stability studies required by Current Good Manufacturing Practice (CGMP) regulations. Stability studies ensure that a drug maintains its safety and effectiveness throughout its shelf life.
The recalled product
- Product
- Clobetasol Propionate Shampoo, 0.05%, 4oz (118 mL) bottles, Rx Only, Distributed by: Akorn Operating Company, LLC., Gurnee, IL 60031. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Dermatological
- Hazard
- cgmp-deviation
- incomplete-stability-data
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27